Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nyxoah SA (NYXH) Fair Value & Analysis

Healthcare · US · Market cap $160M

Price$1.57
Fair Value$2.51
Upside+59.9%
Quality95/100
Evidence: Low Range $1.88 – $3.14

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Nyxoah SA (NYXH) currently trades at $1.57, while our model-based Fair Value estimate is $2.51 — implying the stock looks roughly 59.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -60% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -38% Medline Inc (MDLN) -16% Becton, Dickinson and Company (BDX) -26% Alcon Inc (ALC) -32%

Frequently asked questions

Is Nyxoah SA (NYXH) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.51 versus a price of $1.57 — about +60% (undervalued). Model-based estimate, not financial advice.
What is the fair value of NYXH?
Our 21-model fair value for Nyxoah SA is $2.51 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.57.
What is the quality score of NYXH?
Nyxoah SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.